Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/24 10:00:16 pm
113.61 USD   +0.15%
07:38p JOHNSON & JOHNS : Hepatitis B Virus Market (HBV) Review with 2016-20..
06:51p JOHNSON & JOHNS : Davenport Co buys $162,560,871 stake in Johnson & ..
03:17p JOHNSON & JOHNS : As achievement gap widens, Phoenixville schools se..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA Grants Priority Review to J&J's Bedaquiline Tuberculosis Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
12/31/2012 | 04:02pm CEST
   By Nathalie Tadena 

The Food and Drug Administration has granted accelerated approval for Johnson & Johnson's (JNJ) drug to treat a drug-resistant form of tuberculosis.

The drug, bedaquiline, has faced concerns about an imbalance of deaths seen in clinical studies. J&J's Janssen Research & Development had asked the FDA for accelerated approval of bedaquiline, which is a type of temporary approval based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group--but the prescribing information for the treatment will include boxed warnings regarding increased risk of death.

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether bedaquiline played a role in deaths seen in clinical studies. While the FDA has said the safety data currently available for bedaquiline suggest the product appears safe, there is a potential for the highest dose of the product to cause a small change in the heart's rhythm. The FDA had said there wasn't enough data to rule out potential drug side effects on the liver and the heart. There were more deaths seen among patients being treated with bedaquiline although most of the deaths were attributed to the underlying disease.

The consumer group Public Citizen has strongly opposed the accelerated approval of bedaquiline because clinical trials showed the drug could be highly dangerous.

Only about 100 cases of drug-resistant TB are seen each year in the U.S. but the problem is more severe in typically poor countries outside the U.S.

Tuberculosis is a bacterial infection that mostly involves the lungs. It is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Bedaquiline is designed to work in a new way to treat TB and would be used with other drugs.

However, there is evidence that some forms of TB can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the worldwide control of tuberculosis."

Tuberculosis can be fatal if it's not properly treated.

Write to Nathalie Tadena at nathalie.tadena@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
07:38p JOHNSON & JOHNSON : Hepatitis B Virus Market (HBV) Review with 2016-2025 Forecas..
06:51p JOHNSON & JOHNSON : Davenport Co buys $162,560,871 stake in Johnson & Johnson
03:17p JOHNSON & JOHNSON : As achievement gap widens, Phoenixville schools seek ways to..
10/22 JOHNSON & JOHNSON : to buy wind power in the US
10/22 JOHNSON & JOHNSON : Carlton Hofferkamp Jenks Wealth Management buys $2,342,903 s..
10/21 JOHNSON & JOHNSON : U.s. fda approves vermox chewable (mebendazole) for treatmen..
10/21 JOHNSON & JOHNSON : E.ON inks 100MW wind power deal with Johnson & Johnson
10/20 JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2016
10/20 JOHNSON & JOHNSON : Findings from Johnson & Johnson Broaden Understanding of Imm..
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
More news
Sector news : Pharmaceuticals - NEC
04:32pDJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
12:46pDJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:01p My Income Portfolio Quarterly Update (Q3 2016)
10:27a JOHNSON & JOHNSON : Dark Pool Indicator Flashes Warning
10/23 How The Yield On Cost Can Be Misleading
10/22 Generic drug makers scrambling to preserve marketing approvals of generic ver..
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
Financials ($)
Sales 2016 72 104 M
EBIT 2016 21 901 M
Net income 2016 16 365 M
Finance 2016 9 240 M
Yield 2016 2,77%
P/E ratio 2016 19,16
P/E ratio 2017 16,87
EV / Sales 2016 4,18x
EV / Sales 2017 3,84x
Capitalization 310 358 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results